From: A continuous repetitive task to detect fatigability in spinal muscular atrophy
Gender | Age (y) | Disease | Disease duration (y) | ambulation | Slopea |
---|---|---|---|---|---|
Male | 16.92 | Duchenne | 15.42 | non-ambulant | 34.5 |
Female | 30.25 | SMA type 2 | 29.50 | non-ambulant | 21.8 |
Male | 23.75 | SMA type 2 | 22.83 | non-ambulant | 21.6 |
Male | 7.68 | SMA type 2 | 7.39 | non-ambulant | 9.9 |
Female | 7.69 | SMA type 2 | 7.19 | non-ambulant | 6.0 |
Male | 13.49 | SMA type 2 | 12.66 | non-ambulant | 5.0 |
Female | 70.28 | SMA type 2 | 69.37 | non-ambulant | 3.2 |
Female | 21.40 | SMA type 2 | 21.06 | non-ambulant | 2.2 |
Male | 9.54 | SMA type 2 | 8.74 | non-ambulant | 1.6 |
Male | 48.59 | SMA type 3b/4 | 44.09 | non-ambulant | 1.5 |
Female | 25.94 | SMA type 2 | 25.52 | non-ambulant | 1.4 |
Female | 38.77 | SMA type 3a | 37.61 | non-ambulant | 1.4 |
Female | 24.41 | SMA type 2 | 22.91 | non-ambulant | 1.2 |
Female | 5.69 | SMA type 2 | 4.61 | non-ambulant | 1.1 |
Male | 75.70 | PMA | 19.70 | ambulant | 0.8 |
Male | 9.56 | Becker myotonia | 8.14 | ambulant | 0.7 |
Female | 37.98 | SMA type 2 | 37.44 | non-ambulant | 0.6 |
Female | 9.95 | SMA type 3a | 8.29 | non-ambulant | 0.6 |
Female | 5.69 | SMA type 2 | 4.69 | non-ambulant | 0.5 |
Female | 29.51 | Healthy control | na | ambulant | 0.5 |
Male | 38.00 | SMA type 3b/4 | 13.50 | ambulant | 0.4 |
Male | 13.33 | Duchenne | u | non-ambulant | 0.4 |
Female | 13.64 | SMA type 2 | 12.93 | non-ambulant | 0.4 |
Male | 8.92 | SMA type 3a | 7.33 | ambulant | 0.2 |
Male | 21.98 | SMA type 3b/4 | u | ambulant | 0.2 |
Female | 12.08 | SMA type 2 | 11.33 | non-ambulant | 0.2 |
Female | 21.83 | SMA type 3a | 20.42 | non-ambulant | 0.2 |
Female | 7.73 | HMSN | 6.40 | ambulant | 0.2 |
Male | 13.34 | Duchenne | 11.84 | non-ambulant | 0.1 |
Male | 34.86 | SMA type 3b/4 | 31.36 | ambulant | 0.1 |
Male | 8.41 | Duchenne | u | ambulant | 0.1 |
Male | 14.62 | Duchenne | u | ambulant | 0.1 |
Female | 15.25 | HMSN | 13.92 | ambulant | 0.1 |